RECRUITING

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

Official Title

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)

Quick Facts

Study Start:2025-06
Study Completion:2029-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06579469

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).
  2. * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
  3. * Age ≤ 30 years at CAR T cell infusion.
  1. * Active malignancy other than the disease under study.
  2. * Planned consolidative HSCT within 3 months post CAR T cell infusion.
  3. * Received or planned additional disease directed therapy post CAR T cell infusion.
  4. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Contacts and Locations

Study Contact

Rebecca Epperly, MD
CONTACT
866-278-5833
referralinfo@stjude.org

Principal Investigator

Rebecca Epperly, MD
PRINCIPAL_INVESTIGATOR
St. Jude Children's Research Hospital

Study Locations (Sites)

St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
United States

Collaborators and Investigators

Sponsor: St. Jude Children's Research Hospital

  • Rebecca Epperly, MD, PRINCIPAL_INVESTIGATOR, St. Jude Children's Research Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06
Study Completion Date2029-03

Study Record Updates

Study Start Date2025-06
Study Completion Date2029-03

Terms related to this study

Keywords Provided by Researchers

  • CAR T cell infusion
  • Late Effects

Additional Relevant MeSH Terms

  • B-ALL
  • Hematologic Malignancy
  • Solid Tumor